Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Economic information and modeling report

Modeling overview

17 evidence topics · 15 sources

Summary: sponsor price and revenue statements

The sponsor states that the price of DT120 ODT has not been established. On its third quarter 2026 earnings call, the sponsor stated a commercial pricing corridor of $30,000 to $75,000 per treatment course, based on preliminary feedback from payers on the interventional psychiatry market, and said the corridor would narrow with further payer discussions. In the sponsor's 2026 Investor and Analyst Day presentation, payers name Spravato as the primary price analog, expect FDA-approved psychedelic treatments to be covered, and expect to manage use with prior authorization. The sponsor's 2026 corporate presentation combines 2 patients per month (24 per year), ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and 100K patients treated into a $5B potential gross revenue opportunity, assuming the midpoint of the Spravato surrogate pricing range.

Summary: monitoring-session coding and costs

The sponsor describes a single-visit model reimbursed for the full session; each pivotal dosing session requires 8 hours of monitoring and clearance of the end-of-session checklist, and the sponsor states that existing coding systems could potentially be applied or changed, with reimbursement and coding not yet established. CPT codes 0820T, 0821T, and 0822T describe continuous in-person monitoring and intervention during psychedelic medication therapy, each hour, by a first physician or other qualified health care professional, a concurrent second one, and clinical staff under the direction of a physician or other qualified health care professional. For esketamine, CMS created HCPCS codes G2082 and G2083, effective January 1, 2020 on an interim final basis; G2082 covers an office visit with up to 56 mg of esketamine and 2 hours of post-administration observation, with supply inputs priced at $590.02 for 56 mg and $885.02 for 84 mg.

Summary: analog economic evaluations

ICER's esketamine report used a base-case price of $295 per 28 mg device, estimated an incremental cost-effectiveness ratio of approximately $198,000 per QALY versus no additional treatment, assigned a CPT 99214 visit to each dose for the 2-hour observation, and estimated that 16% of eligible patients could be treated at list price within its $819 million threshold. A separate cost-effectiveness analysis attributed most of the incremental cost to esketamine itself ($16,352), with smaller contributions from physician and medical assistant services ($2,062) and patient time ($2,074), with base case ratios of $237,111/QALY (societal) and $242,496/QALY (healthcare sector). ICER rated the evidence for MDMA-assisted psychotherapy insufficient and used a $10,000 placeholder per course; its micro-costing table lists three 8-hour MDMA sessions (CPT 90837, two therapists) with a cost per session of $1,177 and a total of $7,059; 1.91% of eligible patients could be treated over five years within $735 million per year, and the average annual budget impact per patient was $21,635 in Year one, with cumulative net annual costs of $47,677 per patient in Year five.

Summary: population and burden inputs

The sponsor's funnel counts 50 million U.S. adults with GAD or MDD, 26 million diagnosed, 13 million treated with prescription drugs, and 4.2 million failed by two or more prescription treatments. In the 2022 US National Health and Wellness Survey (N=75,261), adjusted total direct costs were $11,711 for diagnosed and $18,045 for undiagnosed GAD versus $9,190 without GAD, and adjusted indirect costs were $7,507, $7,805, and $6,532 (all comparisons p<0.01). In the 2009 and 2010 Medical Expenditure Panel Survey, annual incremental healthcare expenditure for anxiety disorders was $1657.52 per person, approximately $33.71 billion in total in 2013 US dollars. Among 10,275 patients in a large US health insurance database who started pharmacotherapy for GAD between 2003 and 2007, mean total healthcare costs rose from $4812 before treatment to $7182 during follow-up (p < 0.01). In a MindMed-funded survey of 20 payers covering 130.3 million lives, 40% believed GAD was not a major budgetary concern for their plan, and 70% expected the number of diagnosed individuals seeking reimbursement to increase within 3 years.

ICER review of MDMA-assisted psychotherapy for PTSD: session costs

ResourceResource use (number)CPT codeNumber of therapistsCost per sessionTotal
Psychiatric diagnosis interview examination“1”“90792”“2”“$219”“$438”
90 min preparation session“3”“90837”“2”“$221”“$1,324”
8-hour MDMA session“3”“90837”“2”“$1,177”“$7,059”
90 min integration session“9”“90837”“2”“$221”“$3,971”